ライフサイエンスコーパス: mycosis

1 gal infection and 13 isolates from cutaneous mycosis).

2 human and veterinary patients with pulmonary mycosis.

3 lished model of an allergic bronchopulmonary mycosis.

4 .e., a model of an allergic bronchopulmonary mycosis.

5 a potential source of a vaccine against this mycosis.

6 for endeavors to develop treatments for CNS mycosis.

7 ctive cases of the disseminated form of this mycosis.

8 as a promising model to study this important mycosis.

9 pressed genes (DEGs) was highest during late mycosis (72 h post-infection).

10 Allergic bronchopulmonary mycosis (ABPM) is a hypersensitivity lung disease in whi

11 -old woman who had allergic bronchopulmonary mycosis (ABPM) with nontuberculous mycobacteriosis (NTM)

12 characteristics of allergic bronchopulmonary mycosis (ABPM).

13 ost common form of allergic bronchopulmonary mycosis (ABPM); other fungi, including Candida, Penicill

14 Currently, drugs used clinically for deep mycosis act by binding ergosterol or disrupting its bios

15 Epidemiological data on this type of mycosis are scant.

16 Fusarium Research Center) cultures of novel mycosis-associated fusaria, along with associated, corre

17 All of the mycosis-associated isolates were restricted to FSSC clad

18 Coccidioidomycosis, listed as a priority mycosis by the WHO, is endemic in the United States but

19 Histoplasmosis, a systemic mycosis caused by the fungus Histoplasma capsulatum, pri

20 nicillium marneffei is an emerging dimorphic mycosis endemic in Southeast Asia, and a leading cause o

21 /6 mice develop an allergic bronchopulmonary mycosis following intratracheal inoculation of Cryptococ

22 all of which were from the 44 patients with mycosis fungoides (10/44 patients; 23%).

23 n 18 patients (25%), including 12 of 57 with mycosis fungoides (21%) and six of 16 with Sezary syndro

24 as found to be more prevalent in tumor stage mycosis fungoides (47%) than early stage disease (20%) a

25 patients [82.3%]), had disease classified as mycosis fungoides (48 patients [61.5%]), and had advance

26 tificates for two such cancers, melanoma and mycosis fungoides (a cutaneous lymphoma), using routinel

27 Malignant melanoma and mycosis fungoides (cutaneous T cell lymphoma) are rare m

28 with Sezary syndrome (SS) and erythrodermic mycosis fungoides (e-MF).

29 cutaneous staging system for folliculotropic mycosis fungoides (FMF) has been purported to better est

30 s suggest that patients with folliculotropic mycosis fungoides (FMF) have a worse prognosis than pati

31 The most common variant of CTCL, mycosis fungoides (MF ), is confined to the skin in earl

32 mantle cell lymphoma (MCL) (8% [n = 7]), and mycosis fungoides (MF) (9% [n = 8]).

33 ts with relapsed/refractory PTCL (n = 45) or mycosis fungoides (MF) (n = 7).

34 (CTCL) comprising 10 cases with early-stage mycosis fungoides (MF) and 10 cases with late-stage MF o

35 SHV/HHV-8 is involved in the pathogenesis of mycosis fungoides (MF) and related disorders, we used a

36 Transformed mycosis fungoides (MF) and Sezary syndrome (SS) are curr

37 Mycosis fungoides (MF) and Sezary syndrome (SS) are the

38 ective retinoid that can induce apoptosis of mycosis fungoides (MF) and Sezary syndrome (SS) cells.

39 Advanced mycosis fungoides (MF) and Sezary syndrome (SS) have a p

40 umor, node, metastases (TNM) system used for mycosis fungoides (MF) and Sezary syndrome (SS) is not a

41 CD30 expression of malignant lymphocytes in mycosis fungoides (MF) and Sezary syndrome (SS) is quite

42 p of neoplasms originating in the skin, with mycosis fungoides (MF) and Sezary syndrome (SS) represen

43 ogy and diagnostic techniques as pertains to mycosis fungoides (MF) and Sezary syndrome (SS) since th

44 ic treatment options exist for patients with mycosis fungoides (MF) and Sezary syndrome (SS), but no

45 MTAP in cutaneous T-cell lymphoma subgroups, mycosis fungoides (MF) and Sezary syndrome (SS), is unkn

46 Mycosis fungoides (MF) and Sezary syndrome (SS), the maj

47 treatment of CTCL, with specific emphasis on mycosis fungoides (MF) and Sezary syndrome (SS).

48 Many driver genes are shared by mycosis fungoides (MF) and Sezary syndrome (SS).

49 body against CCR4 approved for treatment for mycosis fungoides (MF) and Sezary syndrome (SS).

50 months) in heavily pretreated patients with mycosis fungoides (MF) and Sezary syndrome (SS).

51 xyadenosine (2-CdA) therapy in patients with mycosis fungoides (MF) and the Sezary syndrome (SS).

52 Sezary syndrome (SS) and tumor-stage mycosis fungoides (MF) are generally incurable with curr

53 Neoplastic T cells in mycosis fungoides (MF) are resistant to apoptotic agents

54 Early-stage mycosis fungoides (MF) has been associated with long sur

55 Mycosis fungoides (MF) is a cutaneous T-cell lymphoma ch

56 Mycosis fungoides (MF) is a low-grade lymphoma of cluste

57 Large cell transformation (LCT) in mycosis fungoides (MF) is generally associated with an a

58 Mycosis fungoides (MF) is the most common form of cutane

59 Mycosis fungoides (MF) is the most common form of cutane

60 Mycosis fungoides (MF) is the most common primary cutane

61 Mycosis fungoides (MF) is the most common primary cutane

62 Mycosis fungoides (MF) is the most common subtype of cut

63 orders originating in the skin, among which, mycosis fungoides (MF) is the most common subtype.

64 Mycosis fungoides (MF) is the most frequent form of cuta

65 Mycosis fungoides (MF) is the most frequent manifestatio

66 Although mycosis fungoides (MF) is typically an indolent disease,

67 Although mycosis fungoides (MF) may arise through persistent anti

68 e cell lymphoma (ALCL) of 2 patients and the mycosis fungoides (MF) of 2 other patients.

69 homa, whereas its expression and function in mycosis fungoides (MF) remain ambiguous.

70 uced type I IFN gene expression in untreated mycosis fungoides (MF) skin lesions compared with that i

71 hrough stage IIA) cutaneous T-cell lymphoma, mycosis fungoides (MF) type, resulted in clinical respon

72 Because patients with mycosis fungoides (MF) usually do not have such antibodi

73 ND1/BCL1 expression in 18 of 30 SS, 10 of 23 mycosis fungoides (MF), and three of 10 primary cutaneou

74 patients with the cutaneous T-cell lymphoma, mycosis fungoides (MF), are seronegative for human T-cel

75 catter T (T(HS)) cells were CD4(+) in CD4(+) mycosis fungoides (MF), CD8(+) in CD8(+) MF, and contain

76 The histopathologic diagnosis of mycosis fungoides (MF), even when clinical manifestation

77 common subtype of cutaneous T-cell lymphoma, mycosis fungoides (MF), is characterized by proliferatio

78 mphoma (CTCL), including Sezary syndrome and mycosis fungoides (MF), is poor.

79 sis of the cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF), is unclear.

80 (CTCL) may present with eczematous lesions, mycosis fungoides (MF), or as exfoliative erythroderma w

81 patients with a diagnosis of CTCL, including mycosis fungoides (MF), Sezary syndrome (SS), or CTCL no

82 Mycosis fungoides (MF), the most common cutaneous T-cell

83 The pathogenesis of mycosis fungoides (MF), the most common cutaneous T-cell

84 nt lymphocytes from Sezary syndrome (SS) and mycosis fungoides (MF), the most common subtypes of cuta

85 f inflammatory cytokines in 12 patients with mycosis fungoides (MF), the most common variant of CTCL.

86 e retrospectively diagnosed with preexistent mycosis fungoides (MF).

87 a worse prognosis than patients with classic mycosis fungoides (MF).

88 A skin biopsy confirmed mycosis fungoides (MF).

89 explored this strategy in a second disease: mycosis fungoides (MF).

90 proliferative disorders (CD30CLPD) and early mycosis fungoides (MF).

91 SS) and primarily cutaneous variants such as mycosis fungoides (MF).

92 od lymphocyte cultures from 19 patients with mycosis fungoides (MF)/Sezary syndrome (SS) stimulated w

93 Advanced-stage mycosis fungoides (MF; stage IIB to IV) and Sezary syndr

94 .1% in Sezary syndrome (n = 17) and 28.6% in mycosis fungoides (n = 21).

95 ients with Sezary syndrome (SS), transformed mycosis fungoides (T-MF), and cutaneous anaplastic large

96 ients with treatment refractory CD4(+) CTCL (mycosis fungoides [MF], n = 38; Sezary syndrome [SS], n

97 pendent prognostic variable in patients with mycosis fungoides after correcting for age, skin, and ly

98 the 54 samples (24%), 12 from patients with mycosis fungoides and 1 from a patient with Sezary syndr

99 have analyzed 51 samples from patients with mycosis fungoides and 15 with Sezary syndrome using meth

100 contributing 52% of the mutational burden in mycosis fungoides and 23% in Sezary syndrome.

101 uding losses on 9p21 in 16% of patients with mycosis fungoides and 46% with Sezary syndrome.

102 amples from 59 patients with Sezary syndrome/mycosis fungoides and 66 samples from unique patients wi

103 lic loss was present in 45% of patients with mycosis fungoides and 67% with Sezary syndrome.

104 eous T-cell lymphoma, and mogamulizumab, for mycosis fungoides and adult T-cell leukaemia/lymphoma.

105 tested SS patients but not in patients with mycosis fungoides and atopic dermatitis or HD.

106 has also shown promise in the management of mycosis fungoides and extranodal natural killer/T-cell l

107 Mycosis fungoides and its leukemic variant, Sezary syndr

108 Mycosis fungoides and Sezary syndrome (MF/SS) are rare i

109 Mycosis fungoides and Sezary syndrome (MF/SS) has an inc

110 that recapitulated the cardinal features of mycosis fungoides and Sezary syndrome and maintained his

111 common in both early and advanced stages of mycosis fungoides and Sezary syndrome and that these gen

112 Advanced mycosis fungoides and Sezary syndrome are life threateni

113 Agents targeting the unique biology of mycosis fungoides and Sezary syndrome are quickly being

114 Mycosis fungoides and Sezary syndrome are the most commo

115 Mycosis fungoides and Sezary syndrome are the most commo

116 Mycosis fungoides and Sezary syndrome are two major form

117 Although the aetiologies of mycosis fungoides and Sezary syndrome are unknown, impor

118 Guidelines for mycosis fungoides and Sezary syndrome clinical trials we

119 Mycosis fungoides and Sezary syndrome comprise the major

120 approximately 30% of patients with advanced mycosis fungoides and Sezary syndrome cutaneous T-cell l

121 aneous T-cell lymphoma (CTCL), including the mycosis fungoides and Sezary syndrome forms of the disea

122 lastic cells (Sezary cells) in patients with mycosis fungoides and Sezary syndrome is essential for d

123 ined lesional skin biopsy specimens from 113 mycosis fungoides and Sezary Syndrome patients for activ

124 lly reverse or suppress the abnormalities of mycosis fungoides and Sezary syndrome to the point at wh

125 ous T-cell lymphoma (CTCL), particularly the mycosis fungoides and Sezary syndrome variants, has been

126 276 patients with cutaneous T cell lymphoma (mycosis fungoides and Sezary syndrome) using 2,4-dinitro

127 oproliferative processes, mainly composed of mycosis fungoides and Sezary syndrome, the aggressive fo

128 inhibit malignant T cells in skin lesions in mycosis fungoides and Sezary syndrome, the most common f

129 Discoveries regarding the pathophysiology of mycosis fungoides and Sezary syndrome, the two most comm

130 ous T-cell lymphoma with special emphasis on mycosis fungoides and Sezary syndrome.

131 candidate tumor suppressor genes involved in mycosis fungoides and Sezary syndrome.

132 h cutaneous T-cell lymphoma (CTCL) including mycosis fungoides and Sezary syndrome.

133 CCR4) antibody approved for the treatment of mycosis fungoides and Sezary syndrome.

134 ctor receptor TNFR2, in 18% of patients with mycosis fungoides and Sezary syndrome.

135 subtypes of the disease, the most common are mycosis fungoides and Sezary syndrome.

136 logy of cutaneous T-cell lymphoma, including mycosis fungoides and Sezary syndrome.

137 Mycosis fungoides and the Sezary syndrome represent a he

138 g, prognosis, and treatment of patients with mycosis fungoides and the Sezary syndrome.

139 S) were required to have stage IA-IIIB CTCL (mycosis fungoides and/or Sezary syndrome) and at least >

140 Sezary syndrome and mycosis fungoides are related chronic lymphoproliferativ

141 n vivo chicken embryo model xenografted with mycosis fungoides cells showed that PKCo blockage abroga

142 n vivo chicken embryo model xenografted with mycosis fungoides cells showed that PKCtheta blockage ab

143 on of a number of PKCo target genes found in mycosis fungoides cells significantly correlated with th

144 f a number of PKCtheta target genes found in mycosis fungoides cells significantly correlated with th

145 The ISCL/EORTC recommends revisions to the Mycosis Fungoides Cooperative Group classification and s

146 aviolet B-related step in the progression of mycosis fungoides from plaque to tumor-stage disease.

147 Mycosis fungoides is a cutaneous malignancy usually foun

148 0.02%, gel in the treatment of patients with mycosis fungoides is effective and safe.

149 Importantly, mycosis fungoides lesions harbor S. aureus, express Y-ph

150 osity was found in over 10% of patients with mycosis fungoides on 9p, 10q, 1p, and 17p and was presen

151 e enrolled adult patients with CD30-positive mycosis fungoides or primary cutaneous anaplastic large-

152 s had anaplastic large-cell lymphoma, 15 had mycosis fungoides or Sezary syndrome (14 with large-cell

153 id) in persistent, progressive, or recurrent mycosis fungoides or Sezary syndrome (MF/SS) cutaneous t

154 ve therefore studied 76 patients with either mycosis fungoides or Sezary syndrome for abnormalities o

155 uppression, such that patients with advanced mycosis fungoides or Sezary syndrome have been compared

156 Among the 8 pivotal trials supporting new mycosis fungoides or Sezary syndrome systemic therapies

157 solid tumours were screened, 35 of whom with mycosis fungoides or Sezary syndrome were enrolled and r

158 We identified 17 patients with mycosis fungoides or Sezary syndrome who either were int

159 ions in patients with relapsed or refractory mycosis fungoides or Sezary syndrome, suggesting it has

160 utaneous T-cell lymphoma (CTCL), or subtypes mycosis fungoides or Sezary syndrome, who had received n

161 nd translational results among patients with mycosis fungoides or Sezary syndrome.

162 A abnormalities in 65 patients with advanced mycosis fungoides or Sezary syndrome.

163 haracteristically slow, we hypothesized that mycosis fungoides originates from an accumulation of lym

164 bility, a study on specimens of relatives of mycosis fungoides patients (MFR) was begun.

165 quence of hMLH1 promoter hypermethylation in mycosis fungoides patients and may prevent transcription

166 in 21/35 (60%) SS patients and in 3/8 (38%) mycosis fungoides patients, all of whom had clonal blood

167 Sezary syndrome and 5 with rapidly enlarging mycosis fungoides plaques or tumors.

168 Fifty-one mycosis fungoides samples were analyzed for microsatelli

169 elated with that of PRKCQ (PKCo) in 81 human mycosis fungoides samples.

170 ed with that of PRKCQ (PKCtheta) in 81 human mycosis fungoides samples.

171 oportion of cutaneous T-cell lymphoma (CTCL)/mycosis fungoides skin samples and in one melanoma.

172 Eighteen cases of early mycosis fungoides were compared with 18 cases of eczemat

173 that only 60% of the deaths attributable to mycosis fungoides were so certified.

174 In total, 260 patients with stage IA to IIA mycosis fungoides who had not used topical mechlorethami

175 Seven patients (44%) had cutaneous (all mycosis fungoides); 4 (25%) had peripheral T cell not ot

176 ease that recapitulates many key features of mycosis fungoides, a common variant of cutaneous T-cell

177 er of the small intestine, eye melanoma, and mycosis fungoides, among men in a European, multicenter

178 ung, and unknown primary tumors, meningioma, mycosis fungoides, and myeloid leukemia.

179 atients had Sezary syndrome, eight (18%) had mycosis fungoides, and one (2%) had primary cutaneous T-

180 lar lymphoma, diffuse large B-cell lymphoma, mycosis fungoides, and peripheral T-cell lymphoma, respe

181 goid, transient acantholytic dermatosis, and mycosis fungoides, and should be considered in elderly p

182 mas, with particular emphasis on tumor stage mycosis fungoides, as it is in these cases that p53 over

183 PTEN may be important in the pathogenesis of mycosis fungoides, but our data imply that this gene is

184 The most common form of CTCL, mycosis fungoides, can be difficult to diagnose, resulti

185 Thus, lesions clinically suspicious for mycosis fungoides, especially those that have failed chr

186 its total absence in PBLs from patients with mycosis fungoides, inflammatory cutaneous or hematologic

187 oma, n = 11; other B-cell lymphomas, n = 10; mycosis fungoides, n = 13; peripheral T-cell lymphoma, n

188 In the subset of patients with mycosis fungoides, P53 mutations were identified in six

189 Eligibility included mycosis fungoides, Sezary syndrome, or primary cutaneous

190 utaneously accessible relapsed or refractory mycosis fungoides, Sezary syndrome, or solid tumours.

191 , 2017, and March 31, 2020, 66 patients with mycosis fungoides, Sezary syndrome, other CTCL, or solid

192 sect key pathological features implicated in mycosis fungoides, the most common cutaneous T-cell lymp

193 evels of TOX were significantly increased in mycosis fungoides, the most common type of cutaneous T-c

194 We also included tissue from two cases of mycosis fungoides, three normal skin biopsies, and three

195 erythroderma or Sezary syndrome and 11 with mycosis fungoides, were studied for the occurrence of st

196 oss on 1p and 9p were found in all stages of mycosis fungoides, whereas losses on 17p and 10q were li

197 MSI and disease progression in patients with mycosis fungoides, with 6 of 15 (40%) patients with MSI

198 Given that mycosis fungoides-cutaneous T-cell lymphoma (MF/CTCL) is

199 from a Macaca nemestrina with CD8(+) T-cell mycosis fungoides-cutaneous T-cell lymphoma.

200 iptomics analysis of skin from patients with mycosis fungoides-type CTCL and an integrated comparativ

201 ype may contribute to disease progression in mycosis fungoides.

202 was associated with an older age of onset of mycosis fungoides.

203 ad chronic myelogenous leukemia, and one had mycosis fungoides.

204 tes the results to skin stage and outcome in mycosis fungoides.

205 10q and MSI in advanced cutaneous stages of mycosis fungoides.

206 arge proportion of patients with early stage mycosis fungoides.

207 ssessment of peripheral blood involvement in mycosis fungoides.

208 feature of the large-cell transformation of mycosis fungoides.

209 usly as a single dose to eight patients with mycosis fungoides.

210 red with the staging system for conventional mycosis fungoides.

211 rived from patients with Sezary syndrome and mycosis fungoides.

212 pression in lesional skin from patients with mycosis fungoides.

213 systemic treatment in patients with stage IB mycosis fungoides.

214 specially in Sezary syndrome and transformed mycosis fungoides.

215 ll documented in a subgroup of patients with mycosis fungoides/Sezary syndrome (MF/SS).

216 A PKCo-dependent transcriptome in mycosis fungoides/Sezary syndrome cells revealed potenti

217 A PKCtheta-dependent transcriptome in mycosis fungoides/Sezary syndrome cells revealed potenti

218 BMC is not due to an intrinsic defect in the mycosis fungoides/Sezary syndrome patients' immune acces

219 ns and outcomes of a subset of patients with mycosis fungoides/Sezary syndrome who were treated with

220 d cases of cutaneous T cell lymphoma (CTCL) (mycosis fungoides/Sezary syndrome) undergo large cell tr

221 ould address an unmet need for patients with mycosis fungoides/Sezary syndrome, a set of incurable di

222 f 31 cutaneous T-cell lymphoma (CTCL) cases (mycosis fungoides/Sezary syndrome, SS) as well as in 5 o

223 e-agent lenalidomide in advanced, refractory mycosis fungoides/Sezary syndrome.

224 DLBCL: OR(allelic) = 1.12, P(trend) = 0.006; mycosis fungoides: OR(allelic) = 1.44, P(trend) = 0.015)

225 s antibody (1) had clinical efficacy against mycosis fungoides; (2) was well tolerated; (3) had a low

226 The frequency of CNS mycosis has increased over the last two decades as more

227 the second report of a transplant-associated mycosis in a heart transplant recipient, extend the prev

228 biological studies involving a case of fatal mycosis in a nonmyeloablative hematopoietic stem cell tr

229 ), a very important opportunistic systematic mycosis in immunocompromised patients.

230 list of fungi recognized as a cause of human mycosis in immunocompromised patients.

231 ndidiasis (OPEC) is a frequent opportunistic mycosis in immunocompromised patients.

232 sis (IA) is the most important opportunistic mycosis in immunosuppressed patients.

233 as emerged as the third most common invasive mycosis in order of importance after candidiasis and asp

234 nsidered the most prevalent endemic systemic mycosis in the Americas, but this situation might be cha

235 Recurrent epidemics of this mycosis in the southwestern United States have contribut

236 plasma capsulatum is the most common endemic mycosis in the United States and frequently presents as

237 Patients with mycosis involving the sinuses, orbits, or central nervou

238 Fungal airway infection (airway mycosis) is an important cause of allergic airway diseas

239 However, little is known whether pulmonary mycosis modulates FOXA2 function.

240 lastomycosis, a respiratory and disseminated mycosis of people and animals worldwide, expression of t

241 is revealed severe allergic bronchopulmonary mycosis pathology in H99-infected mice and evidence of p

242 The majority of therapeutic strategies for mycosis require the protracted administration of antifun

243 iosis marneffei is an emerging opportunistic mycosis seen in severely immunocompromised human immunod

244 ization for Research and Treatment of Cancer/Mycosis Study Group diagnostic criteria.

245 for Research and Treatment of Cancer (EORTC)/Mycosis Study Group Education and Research Consortium (M

246 ation for Research and Treatment of Cancer / Mycosis Study Group.

247 on- for-the-Research-and-Treatment-of-Cancer/Mycosis-Study Group (EORTC-MSG), Invasive-Fungal-Disease

248 stoplasmosis is a worldwide-distributed deep mycosis that affects healthy and immunocompromised hosts

249 lished model of an allergic bronchopulmonary mycosis that has also been used to test a number of immu

250 Talaromycosis (penicilliosis) is an invasive mycosis that is endemic in tropical and subtropical Asia

251 Chromoblastomycosis is a subcutaneous mycosis that remains a therapeutic challenge, with no st

252 omoted protection against C. albicans airway mycosis through an antifungal pathway involving candidal

253 diagnosed in 68 children (55.7%); among them mycosis was identified after radiological examinations i

254 evelop a broad antibody-like reagent against mycosis, wheat germ agglutinin (WGA) was linked to the e

255 s an emerging frequently fatal opportunistic mycosis whose immunopathogenesis is poorly understood.